Factor D Inhibitors for Complement Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders mediated by the complement cascade, such as age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, lack effective inhibitors for the complement pathway, particularly for Factor D, leading to inadequate control of inflammatory responses and cellular damage.
Innovation Solution
Development of specific compounds, represented by Formula 605 or 609, or their pharmaceutically acceptable salts, which act as inhibitors of the complement factor D cascade to treat disorders associated with the alternative, classical, or lectin complement pathways, including inflammatory and immune conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for complement-mediated disorders are used, then existing therapeutic options are limited, but effective control of inflammatory responses and cellular damage cannot be achieved
Solution Approach 1:
The invention segments the complement system into specific targetable components, particularly Factor D of the alternative pathway, allowing for selective inhibition rather than broad suppression. This enables precise control of inflammatory responses while preserving other immune functions.
Solution Approach 2:
The patent introduces Factor D inhibitors as intermediary substances that mediate between the complement system and pathological outcomes. These inhibitors act as molecular mediators to block the alternative pathway's amplification loop, controlling inflammation without completely disabling the immune system.
2Speed
If the alternative complement pathway is activated, then rapid response to pathogens is achieved, but excessive activation leads to cellular damage and inflammatory disorders
Solution Approach 1:
The invention applies partial inhibition of the complement system by specifically targeting Factor D in the alternative pathway. This allows the classical and lectin pathways to remain functional for pathogen detection, while the alternative pathway's excessive amplification is curtailed to prevent cellular damage.
Solution Approach 2:
The patent implements local quality control by introducing Factor D inhibitors that specifically affect the alternative pathway's amplification loop. This creates a localized regulatory mechanism that modulates inflammation in specific tissues or compartments without globally suppressing immune response.
3Adaptability or versatility
If Factor H is non-functional, then alternative pathway activation is unchecked, but this leads to increased C-reactive protein and macular degeneration risk
Solution Approach 1:
The invention creates a synthetic copy of Factor H's protective function through Factor D inhibitors. Since Factor H normally regulates the alternative pathway by preventing uncontrolled C3 convertase formation, the inhibitors replicate this regulatory effect by blocking Factor D, thereby compensating for Factor H deficiency.
Solution Approach 2:
The patent enables the complement system to self-regulate by introducing inhibitors that allow the system to automatically control its own alternative pathway activation. The Factor D inhibitors enable endogenous regulation mechanisms to function properly, reducing reliance on external therapeutic intervention.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.